Your browser is no longer supported. Please, upgrade your browser.
Dare Bioscience, Inc.
Index- P/E- EPS (ttm)-0.81 Insider Own5.57% Shs Outstand50.44M Perf Week-0.63%
Market Cap112.08M Forward P/E- EPS next Y-0.71 Insider Trans0.00% Shs Float47.69M Perf Month-7.10%
Income-32.50M PEG- EPS next Q-0.13 Inst Own4.80% Short Float3.48% Perf Quarter2.61%
Sales- P/S- EPS this Y5.70% Inst Trans- Short Ratio0.46 Perf Half Y18.94%
Book/sh0.15 P/B10.47 EPS next Y-12.70% ROA-320.70% Target Price- Perf Year49.52%
Cash/sh0.13 P/C12.32 EPS next 5Y- ROE- 52W Range0.94 - 3.85 Perf YTD17.16%
Dividend- P/FCF- EPS past 5Y43.30% ROI- 52W High-59.22% Beta1.62
Dividend %- Quick Ratio2.30 Sales past 5Y- Gross Margin- 52W Low66.19% ATR0.07
Employees23 Current Ratio2.30 Sales Q/Q- Oper. Margin- RSI (14)42.21 Volatility4.24% 4.54%
OptionableNo Debt/Eq0.00 EPS Q/Q31.90% Profit Margin- Rel Volume0.28 Prev Close1.55
ShortableYes LT Debt/Eq0.00 EarningsAug 12 AMC Payout- Avg Volume3.60M Price1.57
Recom2.00 SMA20-5.19% SMA50-5.27% SMA200-6.95% Volume1,014,094 Change1.29%
Oct-06-21 08:51AM  
Sep-27-21 08:00AM  
Sep-24-21 11:43AM  
Sep-23-21 08:00AM  
Sep-22-21 08:00AM  
Sep-08-21 08:00AM  
Sep-07-21 08:00AM  
Sep-01-21 08:00AM  
Aug-12-21 08:00AM  
Aug-09-21 08:00AM  
Aug-05-21 08:00AM  
Jul-26-21 08:00AM  
Jul-12-21 05:45AM  
Jul-07-21 08:20AM  
Jun-28-21 08:00AM  
Jun-15-21 12:53PM  
Jun-04-21 08:00AM  
May-13-21 02:30PM  
May-06-21 08:00AM  
Apr-27-21 08:00AM  
Apr-26-21 08:00AM  
Apr-19-21 08:00AM  
Mar-30-21 02:30PM  
Mar-24-21 08:00AM  
Mar-23-21 08:00AM  
Mar-22-21 08:00AM  
Mar-10-21 08:00AM  
Mar-08-21 08:00AM  
Mar-02-21 08:00AM  
Feb-25-21 08:00AM  
Feb-16-21 08:00AM  
Feb-09-21 08:00AM  
Jan-05-21 08:00AM  
Dec-22-20 01:23AM  
Dec-07-20 08:00AM  
Nov-12-20 02:30PM  
Nov-05-20 08:00AM  
Oct-07-20 08:00AM  
Sep-21-20 08:00AM  
Sep-08-20 08:00AM  
Sep-01-20 08:04AM  
Aug-20-20 08:00AM  
Aug-19-20 08:00AM  
Aug-12-20 08:00AM  
Aug-06-20 08:00AM  
Aug-05-20 08:00AM  
Jul-27-20 08:00AM  
Jul-13-20 07:02PM  
Jun-17-20 08:00AM  
Jun-15-20 08:00AM  
Jun-04-20 08:00AM  
May-17-20 03:02PM  
May-14-20 08:00AM  
May-11-20 08:00AM  
May-07-20 08:00AM  
Apr-28-20 08:00AM  
Apr-23-20 08:00AM  
Apr-08-20 04:24PM  
Apr-01-20 08:00AM  
Mar-30-20 02:30PM  
Mar-29-20 09:45AM  
Mar-24-20 08:00AM  
Mar-10-20 08:00AM  
Mar-09-20 08:00AM  
Feb-27-20 08:00AM  
Feb-12-20 04:05PM  
Feb-06-20 08:00AM  
Feb-05-20 08:00AM  
Jan-30-20 08:00AM  
Jan-22-20 06:55AM  
Jan-17-20 12:19PM  
Jan-15-20 08:00AM  
Jan-13-20 07:00AM  
Dec-18-19 08:00AM  
Dec-11-19 08:00AM  
Dec-10-19 08:00AM  
Dec-09-19 07:15AM  
Dec-04-19 03:43PM  
Nov-21-19 08:00AM  
Nov-14-19 08:07AM  
Nov-12-19 08:00AM  
Nov-11-19 08:00AM  
Nov-07-19 08:30AM  
Oct-31-19 08:00AM  
Oct-28-19 08:00AM  
Oct-24-19 08:00AM  
Oct-14-19 08:00AM  
Oct-10-19 08:00AM  
Oct-07-19 08:00AM  
Sep-13-19 02:04PM  
Sep-11-19 08:00AM  
Sep-09-19 12:13PM  
Dare Bioscience, Inc., a clinical-stage biopharmaceutical company, focuses on developing and marketing products for women's health in the United States. The company develops therapies in the areas of contraception, fertility, and sexual and vaginal health. Its products in advanced clinical development include DARE-BV1, a bioadhesive hydrogel formulated with clindamycin phosphate 2% to treat bacterial vaginosis in a single administration that has completed Phase 3 clinical trials; Ovaprene, a hormone-free monthly vaginal contraceptive; and Sildenafil Cream, a cream formulation of sildenafil for topical administration to the vulva and vagina for treatment of female sexual arousal disorder. The company's Phase 1-ready products are DARE-HRT1, a combination of bio-identical estradiol and progesterone intravaginal ring for the treatment of vasomotor symptoms in hormone therapy; DARE-VVA1, a vaginally delivered formulation of tamoxifen to treat vulvar vaginal atrophy in patients with hormone-receptor positive breast cancer; and DARE-FRT1, an intravaginal ring containing bio-identical progesterone for the prevention of preterm birth and broader luteal phase support as part of an in vitro fertilization treatment plan. Its products in pre-clinical stage include DARE-LARC1, a combination product designed to provide reversible contraception; ORB-204 and ORB-214, an injectable formulations of etonogestrel to provide contraception over 6-month and 12-month periods; and DARE-RH1, a non-hormonal contraception for men and women. The company is headquartered in San Diego, California.